Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Gross Margin: 2018-2025

Historic Gross Margin for Akebia Therapeutics (AKBA) over the last 7 years, with Sep 2025 value amounting to 84.03%.

  • Akebia Therapeutics' Gross Margin rose 2187.00% to 84.03% in Q3 2025 from the same period last year, while for Sep 2025 it was 78.99%, marking a year-over-year decrease of 43798.00%. This contributed to the annual value of 60.56% for FY2024, which is 70205.00% up from last year.
  • Latest data reveals that Akebia Therapeutics reported Gross Margin of 84.03% as of Q3 2025, which was down 0.11% from 84.12% recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Gross Margin high stood at 114.53% for Q4 2023, and its period low was 0.79% during Q2 2021.
  • In the last 3 years, Akebia Therapeutics' Gross Margin had a median value of 64.41% in 2024 and averaged 71.74%.
  • Its Gross Margin has fluctuated over the past 5 years, first skyrocketed by 16,960bps in 2021, then crashed by 5,833bps in 2024.
  • Over the past 5 years, Akebia Therapeutics' Gross Margin (Quarterly) stood at 17.42% in 2021, then surged by 8,872bps to 106.15% in 2022, then skyrocketed by 839bps to 114.53% in 2023, then plummeted by 5,833bps to 56.20% in 2024, then surged by 2,187bps to 84.03% in 2025.
  • Its last three reported values are 84.03% in Q3 2025, 84.12% for Q2 2025, and 86.70% during Q1 2025.